

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G
(Rule 13d-102)

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT
TO RULES 13d-1(b),(c) AND (d) AND AMENDMENTS THERETO FILED
PURSUANT TO RULE 13d-2(b)
(Amendment No. 1)¹

Protagonist Therapeutics, Inc.
(Name of Issuer)

Common Stock, \$.00001 par value
(Title of Class of Securities)

74366E102
(CUSIP Number)

December 31, 2020
(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

¹ The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act.

NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

1. Johnson & Johnson
EIN: 22-1024240

2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a)
(b)

3. SEC USE ONLY

4. CITIZENSHIP OR PLACE OF ORGANIZATION
New Jersey

	5.	SOLE VOTING POWER
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH		-0-
	6.	SHARED VOTING POWER
		2,449,183
	7.	SOLE DISPOSITIVE POWER
		-0-
	8.	SHARED DISPOSITIVE POWER
		2,449,183

9. AGGREGATE AMOUNT BENEFICIALLY OWNED
BY EACH REPORTING PERSON

2,449,183

10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9)
EXCLUDES CERTAIN SHARES

11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

5.7%*

12. TYPE OF REPORTING PERSON

CO

* Based on 43,020,000 shares of Common Stock outstanding as of December 31, 2020.

NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

1. Johnson & Johnson Innovation-JJDC, Inc.
EIN: 22-2007137

2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a)
(b)

3. SEC USE ONLY

4. CITIZENSHIP OR PLACE OF ORGANIZATION
New Jersey

	5.	SOLE VOTING POWER
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH		-0-
	6.	SHARED VOTING POWER
		2,449,183
	7.	SOLE DISPOSITIVE POWER
		-0-
	8.	SHARED DISPOSITIVE POWER
		2,449,183

9. AGGREGATE AMOUNT BENEFICIALLY OWNED
BY EACH REPORTING PERSON

2,449,183

10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9)
EXCLUDES CERTAIN SHARES

11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

5.7%*

12. TYPE OF REPORTING PERSON

CO

* Based on 43,020,000 shares of Common Stock outstanding as of December 31, 2020.

AMENDMENT NO. 1 TO SCHEDULE 13G

Reference is hereby made the statement on Schedule 13G filed with the Securities and Exchange Commission by the Reporting Persons with respect to the Common Stock of the Issuer on August 19, 2016 (the "Schedule 13G"). Terms defined in the Schedule 13G are used herein as so defined.

The following items of the Schedule 13G are amended and restated to read in their entirety as follows:

ITEM 1(b) ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES:

7707 Gateway Boulevard, Suite 140, Newark, CA 94560-1160

ITEM 2(b) ADDRESS OF PRINCIPAL BUSINESS OFFICE:

J&J: One Johnson & Johnson Plaza, New Brunswick, NJ 08933

JJDC: 410 George Street, New Brunswick, NJ 08901

ITEM 4 OWNERSHIP:

The information set forth in Rows 5 through 9 and 11 of the cover pages of this Amendment No. 1 to Schedule 13G is incorporated herein by reference.

SIGNATURE

After reasonable inquiry and to the best of their knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete and correct.

Dated: February 1, 2021

JOHNSON & JOHNSON

By: /s/ Matthew Orlando

Name: Matthew Orlando

Title: Secretary

JOHNSON & JOHNSON INNOVATION-JJDC, INC.

By: /s/ Kevin Norman

Name: Kevin Norman

Title: Assistant Secretary